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Abstract
Background: Although sentinel node biopsy (SNB) is becoming the standard approach for axillary
staging in patients with small breast cancer, criteria for patient selection and some technical aspects
of the procedure have yet to be clearly defined. The aim of the present survey was therefore to
investigate the way in which SNB is used by general surgeons working in the Veneto region, Italy.
Methods: A 29-item questionnaire regarding various aspects of SNB practice was mailed to
surgeons in charge of breast surgery in all the 56 surgical centres of the region.
Results: The rate of response to the questionnaire was 82.1% (n = 46); 69.6% (n = 32) of the
respondents routinely perform SNB in their clinical practice. Most of the interviewed surgeons
(93.5%) expressed the belief that the acceptable false negative rate should be ≤5%. However,
among the surgeons who perform SNB, only 34.4% performed more than 20 SNB during the
learning phase. Indications are limited to tumours of ≤1 cm by 31.2% (n = 10) of respondents, ≤2
cm by 46.9% (n = 15) and ≤3 cm by 21.9% (n = 7). Almost all respondents (93.7%) agreed that a
clinically positive axilla is a contraindication to SNB, while opinions differed widely concerning
other potential contraindications. In most of the centres considered, SN identification is
undertaken on the day before surgery using a subdermal injection of 30–50 MBq of 99mTc-albumin-
nanocolloid followed by lymphoscintigraphy.
Conclusions: SNB is currently performed in the majority of hospitals in the Veneto region.
However, the training phase and criteria used for patient selection differ from centre to centre.
Certified training courses and shared guidelines are therefore highly desirable.
Background
For many years, axillary lymph node dissection (ALND)
has been considered the standard of care for patients with
invasive breast cancer. However, two-thirds of women
with early breast cancer do not have nodal metastases and
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gain no therapeutic benefit from ALND. Moreover, the
rate of morbidity following this procedure is high.
Sentinel node biopsy (SNB) for breast cancer was intro-
duced in the mid 1990s as a mini-invasive, sensitive tool
for axillary staging that allows ALND to be avoided if the
sentinel node is metastasis-free. The technique raised
great interest and was rapidly adopted into the clinical
practice.
Some authors have questioned the widespread use of SNB
rather than standard ALND. SNB has not yet been vali-
dated in clinical trials, as is customary before applying a
new medical procedure to clinical practice. All published
phase I-II studies report a low, but significant, rate of false
negative results (SN negative with other axillary nodes
positive) [1] and the long-term impact of under-staging
and possible under-treatment on relapse and mortality
rates is still unclear. As yet, only one randomised trial
reporting outcomes at five-years has appeared in litera-
ture, and it found no difference between the disease-free
survival of patients randomized for ALND or SNB fol-
lowed by ALND only if the SN was positive [2]. However,
because of the relatively small number of patients evalu-
ated (516), no final conclusions can be drawn. Moreover,
it is doubtful whether community general surgeons can
quickly achieve results comparable with those published
by academic centres with extensive specific experience.
However, in a recent Consensus Conference (Philadel-
phia, April 2001) [3], it was claimed that SNB, as a diag-
nostic procedure, does not require validation by clinical
trials and that the experience so far obtained with obser-
vational studies is reliable enough to warrant its use in
clinical practice. Moreover, the Italian media have
reported that SNB is as a harmless and safe procedure
whereas ALND is obsolete. Therefore many patients with
breast cancer specifically demand SNB and refuse to enter
randomised clinical trials comparing the two procedures.
The use of SNB has thus spread rapidly from large aca-
demic surgical centres to small community hospitals, but
many aspects of patient selection criteria and some tech-
nical details of the procedure still need to be better
defined and are currently open to personal interpretation.
The purpose of this paper was therefore to investigate how
general surgeons involved in breast cancer treatment in
the Veneto region, in North East Italy, use SNB in their
clinical practice. To our knowledge, no papers regarding
this issue have yet been published in Europe, although
some surveys have been carried out in the United States
and Canada [4-7].
Methods
In May 2003, GIVOM (Gruppo Interdisciplinare Veneto
di Oncologia Mammaria), an Italian co-operative group
dedicated to the study of breast cancer, mailed a 29-item
questionnaire [see Additional file 1] to surgeons in charge
of breast cancer surgery in all the 56 surgical units of the
Veneto region, which has a population of 4.5 million.
Overall, the surgical units operate on approximately 3,500
breast cancer patients a year. Reference was made to the
Venetian Tumour Registry (data not shown) to establish
the number of procedures performed for breast cancer sur-
gery in each unit. The settings for the clinical practice of
surgeons were classified as community, regional and
academic.
A cover letter was sent with the questionnaire to provide
background information and explain the study aims. The
questionnaire contained multiple-choice questions subdi-
vided into three sections.
Section 1 was designed to ascertain whether the inter-
viewed surgeon currently used SNB rather than ALND out-
side the setting of clinical trials, whether s/he believed that
scientific experience gained so far is sufficient to justify the
use of SNB in clinical practice and whether s/he felt
obliged to perform the procedure because of patients'
demands, induced by media propaganda.
Section 2 contained questions concerning training sur-
geons had undergone before using the procedure as stand-
ard practice, criteria they used in selecting candidates for
SNB and the technique they used for sentinel node
localisation.
Section 3 investigated technical aspects of the procedure,
such as type of tracer and doses used, site of injection, tim-
ing of surgery.
A second questionnaire was mailed to all surgeons who
had not returned the first questionnaire within 30 days.
Responses, fed into a data-base, were analysed using
counts and percentages.
Results
Forty-six out of 56 surgeons (82.1%) completed and
returned the questionnaire. Of the 46 completed ques-
tionnaires, 32 were returned following the first mailing,
and 14 following the second. Practice setting and volume
of breast cancer surgery did not influence the response
rates, as shown in Table 1.
Section 1 (Perceptions and attitudes)
Thirty-two (69.6%) of the respondents currently perform
SNB in their clinical practice. All the 8 respondentBMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/2
Page 3 of 7
(page number not for citation purposes)
surgeons in charge of breast surgery at academic centres
reported that they used SNB, while only 11/13 surgeons
working in regional centres and 13/25 of those working in
community hospitals performed this procedure (100%,
84.6% and 52.0% respectively, p = 0.004; χ2 for linear
trend) (Table 1). SNB was used more frequently by sur-
geons who perform over 60 breast cancer operations per
year than by those with a smaller case-load, but the differ-
ence was not significant (Table 1).
Of the 14 surgeons who did not perform this procedure,
11 stated that their reasons for abstaining were organisa-
tional (nuclear medicine and/or probe for radio-guided
surgery not available), while the remaining 3 believed that
SNB is still an experimental procedure.
Forty-three of the 46 surgeons (93.5%) expressed a belief
that experience gained so far world-wide with this tech-
nique is sufficient to warrant its use in clinical practice.
However, 31 surgeons (67.4%) believed that the indica-
tions for, and limitations of, the procedure have yet to be
defined. Many of respondents (72.7%) felt they were
somehow obliged to offer SNB as standard practice
because some patients insist on undergoing this tech-
nique as they are influenced by media propaganda in
favour of SNB.
Most respondents (93.5%) stated that the highest accept-
able false-negative rate should be equal to or less than 5%;
the remaining 6.5% considering rates of up to 10%
acceptable.
Section 2 (Training and criteria for use)
The time distribution of centres routinely performing sen-
tinel node biopsy is shown in Figure 1.
The number of cases of SNB undertaken during the learn-
ing phase before abandoning ALND varied: out of the 32
respondents who currently used SNB, 7 (21.9%) per-
formed less than 10 training procedures, 14 (43.7%)
between 10 and 20 procedures, 4 (12.5%) between 20
and 30 procedures and 7 (21.9%) more than 30
procedures.
The size of the primary breast tumour strongly influenced
selection of candidates for the procedure: 10/32 surgeons
(31.2%) performed SNB only if the tumour was <1 cm,
15/32 (46.9%) extended the indication up to 2 cm and 7/
32 (21.9%) up to 3 cm. None of the respondents per-
formed SNB in patients with tumour diameters greater
than 3 cm.
The opinions of respondents concerning contraindica-
tions to SNB are summarized in Table 2. Most considered
a clinically positive axilla an absolute contraindication
(93.7%). Neoadjuvant chemotherapy and multi-centric
lesions were the other most frequently cited contraindica-
tions (78.1% and 71.9%, respectively).
Twenty-eight surgeons (87.5%) performed SNB in
patients with ductal carcinoma in situ (DCIS): 6/32
(18.7%) in all cases and 22/32 (68.7%) only if the
tumour diameter was greater than 2 cm.
The surgical strategies for breast cancer treatment using
SNB varied: 37.5% of respondents preferred to perform a
one-step operation under general anaesthesia, using fro-
zen section examination of the SN and immediate radical
breast operation associated with ALND in patients with
positive SN; 34.4% performed radical treatment of the pri-
mary tumour and SNB, waited for definitive SN histology
and then, if deemed necessary, performed a delayed
ALND. Finally, 28.1% performed primary tumour biopsy
and SNB under local anaesthesia, waited for definitive his-
tology and then performed radical breast surgery associ-
ated with ALND if requested.
Table 1: Rate of response to the questionnaire and number of centres performing SNB according to practice setting and breast surgery 
case-load
Variable Total Complete response Centres performing SNB
N%N%
Practice setting
Community 30 25 83.3 13 52.0
Regional 16 13 81.2 11 84.6
Academic 10 8 80.0 8 100.0
Annual volume of breast 
surgery procedures
≤30 cases 11 8 72.7 5 62.5
31–60 cases 20 17 85.0 10 58.8
>60 cases 25 21 84.0 17 80.9BMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/2
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In order to localise SNs, 27 surgeons out of 32 (84.4%)
used a radio-tracer (99mTc-albumin nanocolloid), either
alone (65.6%) or combined (18.7%) with blue dye injec-
tion (Patent Blue). Only 5/32 (15.6%) used blue dye
alone.
Section 3 (Technical details)
In all the 27 centres in which radioisotopes were used, the
tracer injection was made the day before surgery, and lym-
phoscintigraphy was performed in all but one of the
centres.
The dose of radioisotope injected was less than 30 MBq in
2 centres (7.4%), between 30 and 50 MBq in 21 centres
(77.7%) and more than 50 MBq in 4 centres (14.8%).
In patients with palpable tumours, the radiotracer was
injected subdermally in the tumour area in 24/27 centres
(88.9%), while in 3 centres deep peritumoural injection
was used. Blue dye injection, if associated, was made in
the subareolar plexus a few minutes before skin incision.
SNB was performed in patients with non-palpable
tumours in 25/27 centres: the radiotracer was injected
subdermally in the cutaneous projection of the tumour in
12/25 centres (48%), deeply in the peritumoural area in
5/25 (20%) and in the subareolar plexus in 5/25 (20%),
while 3/25 centres (12%) reported combinations of dif-
ferent routes of injection.
When more than one hot axillary node was identified
intra-operatively by the gamma probe, 14/27 surgeons
(51.9%) removed the hottest node together with all nodes
with similar radioactivity levels, 9/27 (33.3%) excised all
nodes with radioactive counts higher than 10% of those
measured in the hottest node and 4/27 (14.8%) removed
all nodes with a radioactivity level greater than that of
background activity.
Of the 27 surgeons, 20 (74.1%) routinely searched for
internal mammary nodes using the gamma probe, even if
their attitudes toward biopsy differed: if hot internal
mammary nodes were found, biopsy was always per-
formed by 8/20 (40%), while 6/20 (30%) performed
Table 2: Factors considered contraindications to sentinel node biopsy by the 32 surgeons who currently perform SNB in their clinical 
practice
FACTORS N of surgeons %
Clinically positive axilla 30 93.7
Patients given neo-adjuvant CT 25 78.1
Multi-centric tumours 22 71.9
Previous homo-lateral quadrantectomy in the upper-outer quadrant (without axillary surgery) 12 37.5
Previous homo-lateral axillary incision (i.e. for prosthesis insertion) 8 25.0
Previous tumour excision 41 2 . 5
Non-palpable tumours 13 . 1
Percentage of centres performing sentinel node biopsy as  standard practice from 1998 to 2003 Figure 1
Percentage of centres performing sentinel node biopsy as 
standard practice from 1998 to 2003.
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biopsy only if no axillary sentinel node was found and 6/
20 (30%) never performed a biopsy.
Discussion
Although an enormous number of scientific papers on
SNB in breast cancer patients have appeared in literature,
few investigate the ways in which this technique is used by
general surgeons outside the ambit of specialty centres [4-
7].
The findings in the present survey show that the surgical
community in the Veneto region believes that the scien-
tific data so far accumulated in phase I-II studies is suffi-
cient to warrant the use of SNB in clinical practice, and
most surgeons interviewed in the present study currently
use this technique as the standard method for axillary
staging in patients with small breast cancer. Most of the
surgeons who do not yet use this technique in clinical
practice are hindered by organisational problems or are
still in the learning phase, while only a small minority
believe that this procedure is still at an experimental stage
and cannot yet be used in clinical practice.
However, the answers given to some specific items in the
questionnaire give rise to some doubts, and indicate
potential problems. One concerns the potential false neg-
ative rate and another the length of the learning phase.
False negative SNB, defined as the occurrence of a negative
SN in the presence of other metastatic axillary nodes, may
have untoward clinical consequences. More than 90% of
the surgeons interviewed considered 5% the maximal
acceptable false negative SNB rate, in agreement with the
rates reported by some experienced surgeons and with the
recommendations expressed by the panel of the Consen-
sus Conference of Philadelphia [3]. However, the rate of
SN identification and the incidence of false negative cases
reported in literature vary greatly The average rate of SN
identification using blue dye or radioactive colloids is
more than 90%, but results ranging from 65% to 98%
have been reported [1].
Even if false negative rates of 0% have been reported [8,9],
most mono-institutional studies report rates ranging from
5% to 10%, even in experienced hands [1,2,10,11]. Multi-
centre studies involving community general surgeons are
more likely to reflect the situation in the clinical practice
setting, and often present false negative rates above 10%.
For instance, in a multi-institutional study reported by
Krag et al., involving 443 patients and 11 surgeons, the
false negative rate was 11.4% [12]. In a survey evaluating
the outcomes of SNB in 12 hospitals in British Columbia,
Chua et al. reported a false negative rate of 22% [6].
Regarding the Veneto region, in 1999 a pilot study on SNB
on 126 breast cancer patients enrolled in four hospitals
reported a false negative rate of 10.9% [13].
It is well known that both the detection rate and the false
negative rate improve if the surgeon is given a formal,
chaperoned training course and if an adequate number of
SNB procedures are performed together with complete
axillary dissection [14]. Most authors suggest that a sur-
geon should perform at least 20 to 30 training procedures
and achieve a detection rate of >90% and a false negative
rate of <5% before embarking on SNB without concomi-
tant axillary dissection [3].
In Italy, there is no program for formal, proctored courses
for SNB and no certification is required for performing
SNB in clinical practice. Therefore most of the interviewed
surgeons are self-taught and more than half of them have
performed less than 20 training procedures. In this set-
ting, it appears quite optimistic to expect a false negative
rate of <5%, especially in centres where breast cancer sur-
gery is only occasionally performed. Among the respond-
ents, 71.7% felt somehow obliged to offer SNB as
standard practice because of patients' demands and press
campaigns, and this may have played a role in curtailing
the duration of the training period. Similar data have been
reported in American and Canadian surveys, which
underline the lack of adequate training and the variability
in the learning curve, raising doubts concerning the aver-
age quality of SNB performed in clinical practice [6,7].
A further point of interest is the variability in selection cri-
teria for SNB candidates. The size of the primary tumour
is a major criterion for patient selection, since it is strictly
related to the probability of nodal involvement. There-
fore, the performance of SNB in patients with large
tumours increases the number of false negative cases and
decreases the advantages of the procedure since more
patients undergo a completion axillary dissection because
of a positive SN. The Consensus Conference Panel of Phil-
adelphia recommends SNB in patients with breast
tumours ≤3 cm [3], although some authors have reported
that this technique is reliable also in patients with larger
tumours [15,16]. The present survey shows that there is
little agreement on the upper dimensional limit for per-
forming SNB without concomitant axillary dissection:
31.2% of the surgeons interviewed limit SNB to tumours
<1 cm, 46.9% to tumours <2 cm and 21.9% to tumours
up to 3 cm.
In view of the fact that indications for SNB in patients with
DCIS are still controversial, the percentage (87.5%) of sur-
geons in the Veneto region who routinely used this
approach appears high. By comparison, Lucci et al. report
that only 28% of the American surgeons interviewed in
their survey perform SNB in cases of high-grade DCIS [7].BMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/2
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In the present survey, the presence of a clinically positive
axilla is considered an absolute contraindication to SNB
by almost all the respondents, while only about one third
of them abstain from SNB in cases of prior axillary proce-
dures or extensive homo-lateral breast surgery. Interest-
ingly, 21.9% of the interviewed surgeons perform SNB
outside of clinical trials also in patients with locally
advanced tumours who have undergone neoadjuvant
chemotherapy. The presence of non-palpable tumours or
a history of previous tumour biopsy is no longer consid-
ered a contraindication to the procedure.
In their survey on SNB in British Columbia, Chua et al.
also reported variability in patient selection criteria and a
lack of uniform indications for SNB [6].
Overall, the technical aspects of the procedure for localis-
ing SN are quite uniform throughout the Veneto region
and are consistent with the protocol used by GIVOM for
its ongoing clinical trial on SNB [17]: in most centres, a
subdermal injection of 30–50 MBq of 99mTc-albumin
nanocolloids followed by lymphoscintigraphy is per-
formed the day before surgery. However, different sites are
used for tracer injection in patients with non-palpable
lesions. Different opinions were expressed concerning the
nodes that should be removed in patients with axillary
multiple hot nodes. In the presence of hot internal mam-
mary nodes, which is rare if subdermal tracer injection is
used, most surgeons proceed with biopsy.
Finally, the strategy of surgical treatment varies, since
some surgeons perform SNB with frozen section examina-
tion as part of a one-step treatment, while others routinely
follow a two-step procedure. The surgical strategy should
be tailored to the tumour characteristics and to the
patient's wishes, but some key issues, such as the sensitiv-
ity of frozen-section examination in detecting nodal
micrometastases, should be better defined in order to
establish the ideal procedure.
Conclusions
In conclusion, the present survey shows that SNB is widely
used in surgical practice in the Veneto region, although
some centers are still hampered by organisational prob-
lems. However, there are relevant differences between the
various centres for duration of the learning phase, criteria
for patient selection and some technical aspects. There-
fore, the surgical treatment given by different hospitals in
the Veneto region to women with breast cancer has not
been adequately standardized and depends greatly upon
the experience and the personal opinions of the surgeons
involved. Since the long-term consequences of leaving
undetected cancer in the axilla are still unknown, every
effort should be made to minimise false negative rates.
A self-taught technique and the lack of an adequate learn-
ing curve are clearly a wrong way to approach the utiliza-
tion of SNB in clinical practice.
The health authority should therefore promote and sup-
port adequate formal training courses to teach inexperi-
enced surgeons to perform SNB correctly, and a quality
control programme is urgently required. On the other
hand, all the necessary resources should be supplied:
gamma-detecting probes for all the surgical units and
human resources for the nuclear medicine services, in
order to satisfy the increasing demand for
lymphoscintigraphy.
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